First Time Loading...
A

Ambrx Biopharma Inc
NYSE:AMAM

Watchlist Manager
Ambrx Biopharma Inc
NYSE:AMAM
Watchlist
Price: 28 USD 0.07% Market Closed
Updated: May 5, 2024

Ambrx Biopharma Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ambrx Biopharma Inc
Cash from Operating Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
A
Ambrx Biopharma Inc
NYSE:AMAM
Cash from Operating Activities
-$68.7m
CAGR 3-Years
-192%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$22.8B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
14%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$8B
CAGR 3-Years
-5%
CAGR 5-Years
1%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$8.5B
CAGR 3-Years
-7%
CAGR 5-Years
-6%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.5B
CAGR 3-Years
3%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.6B
CAGR 3-Years
21%
CAGR 5-Years
16%
CAGR 10-Years
23%

See Also

What is Ambrx Biopharma Inc's Cash from Operating Activities?
Cash from Operating Activities
-68.7m USD

Based on the financial report for Dec 31, 2022, Ambrx Biopharma Inc's Cash from Operating Activities amounts to -68.7m USD.

What is Ambrx Biopharma Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-192%

Over the last year, the Cash from Operating Activities growth was -54%. The average annual Cash from Operating Activities growth rates for Ambrx Biopharma Inc have been -192% over the past three years .